Wuxi Apptec, Laboratory Testing Division

Wuxi Apptec, Laboratory Testing Division company information, Employees & Contact Information

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated.“ Our state-of-the-art Laboratory Testing Division in New Jersey provides leading bioanalytical & drug metabolism contract research services to a global customer base of pharmaceutical, biotech & agrochemical firms. Our bioanalytical services support a wide range of compounds-small & large molecules, new modalities including oligonucleotides, ADC, bispecific antibodies & more-from discovery to preclinical IND-enabling & regulated clinical studies. Capabilities include LC-MS/MS & immunochemistry platforms for GLP & non-GLP & customized Central Laboratory services to facilitate global clinical studies. Our comprehensive drug metabolism services are tailored to support the entire drug development cycle, from early discovery through IND-enabling to late-stage clinical development. Capabilities include in vivo pharmacokinetics, in vitro ADME, in vitro & in vivo biotransformation, & non-clinical radiolabel ADME (mass balance & QWBA).

Company Details

Employees
85
Founded
-
Address
107 Morgan Lane, Plainsboro,nj 08536,united States
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Plainsboro, NJ
Looking for a particular Wuxi Apptec, Laboratory Testing Division employee's phone or email?

Wuxi Apptec, Laboratory Testing Division Questions

News

WuXi AppTec Marks 25 Years as a Trusted Partner in Global Drug Discovery, Development, and Manufacturing - Reuters

WuXi AppTec Marks 25 Years as a Trusted Partner in Global Drug Discovery, Development, and Manufacturing Reuters

WuXi AppTec Awarded Gold Medal by EcoVadis Sustainability Rating for Second Consecutive Year - Yahoo Finance

WuXi AppTec Awarded Gold Medal by EcoVadis Sustainability Rating for Second Consecutive Year Yahoo Finance

How WuXi AppTec Embeds Quality: A Global Blueprint for Trust and Excellence - openPR.com

How WuXi AppTec Embeds Quality: A Global Blueprint for Trust and Excellence openPR.com

RMB6.88B Returned to Shareholders: WuXi AppTec's Massive Dividend & Buyback Plan Hits 70% of 2024 Profit - Stock Titan

RMB6.88B Returned to Shareholders: WuXi AppTec's Massive Dividend & Buyback Plan Hits 70% of 2024 Profit Stock Titan

A Concise Flow Synthesis of the IKZF2 Glue Degrader DKY709 - ACS Publications

A Concise Flow Synthesis of the IKZF2 Glue Degrader DKY709 ACS Publications

WuXi AppTec Implements Its First Interim Dividend Plan, Distributing RMB1.03 Billion in Cash Dividends - The Manila Times

WuXi AppTec Implements Its First Interim Dividend Plan, Distributing RMB1.03 Billion in Cash Dividends The Manila Times

NAMSA Acquires the U.S. Medical Device Testing Operations of WuXi AppTec, Solidifying its Position as the Leader in MedTech Testing and Clinical Research - Business Wire

NAMSA Acquires the U.S. Medical Device Testing Operations of WuXi AppTec, Solidifying its Position as the Leader in MedTech Testing and Clinical Research Business Wire

WuXi AppTec Nantong Site Receives 2025 Architizer A+Award for Its Unique Blend of Technology and Humanity - WuXi AppTec

WuXi AppTec Nantong Site Receives 2025 Architizer A+Award for Its Unique Blend of Technology and Humanity WuXi AppTec

Unlocking Europe's Pharma Potential: How WuXi AppTec Bridges the Innovation-to-Market Gap - openPR.com

Unlocking Europe's Pharma Potential: How WuXi AppTec Bridges the Innovation-to-Market Gap openPR.com

DNA-Compatible Huisgen [3 + 2] Cycloaddition of In Situ Formed Nitrile Oxides with Alkenes or Alkynes to Synthesize Isoxazolines or Isoxazoles - ACS Publications

DNA-Compatible Huisgen [3 + 2] Cycloaddition of In Situ Formed Nitrile Oxides with Alkenes or Alkynes to Synthesize Isoxazolines or Isoxazoles ACS Publications

WuXi AppTec Looks to Extend CRDMO Platform to Saudi Arabia as It Signs Strategic MoUs with NEOM and Ministry of Health - PR Newswire

WuXi AppTec Looks to Extend CRDMO Platform to Saudi Arabia as It Signs Strategic MoUs with NEOM and Ministry of Health PR Newswire

WuXi AppTec's New EU Batch Release Services: What This Means for European Biotech - openPR.com

WuXi AppTec's New EU Batch Release Services: What This Means for European Biotech openPR.com

WuXi AppTec Issues Positive Profit Alert for the First Half of 2025 - Yahoo Finance

WuXi AppTec Issues Positive Profit Alert for the First Half of 2025 Yahoo Finance

WuXi AppTec Breaks Ground on New Site in Singapore to Better Support Global Customers - WuXi AppTec

WuXi AppTec Breaks Ground on New Site in Singapore to Better Support Global Customers WuXi AppTec

WuXi AppTec Achieves Strong Growth in Revenue and Profit for Q2 and H1 2025, H1 Revenue from Continuing Operations[1] Up 24.2% YoY, and Adjusted Non-IFRS Net Profit Up 44.4% YoY; Backlog for Continuing Operations Up 37.2% YoY - Yahoo Finance

WuXi AppTec Achieves Strong Growth in Revenue and Profit for Q2 and H1 2025, H1 Revenue from Continuing Operations[1] Up 24.2% YoY, and Adjusted Non-IFRS Net Profit Up 44.4% YoY; Backlog for Continuing Operations Up 37.2% YoY Yahoo Finance

WuXi AppTec Expands Site in California for Pharmaceutical R&D Services - WuXi AppTec

WuXi AppTec Expands Site in California for Pharmaceutical R&D Services WuXi AppTec

WuXi AppTec Q1 2025 Revenue, Profit Resume Double Digit Growth, Revenue Up 21.0% YoY, Adjusted Non-IFRS Net Profit Up 40.0% YoY; Backlog for Continuing Operations Up 47.1% YoY - Yahoo Finance

WuXi AppTec Q1 2025 Revenue, Profit Resume Double Digit Growth, Revenue Up 21.0% YoY, Adjusted Non-IFRS Net Profit Up 40.0% YoY; Backlog for Continuing Operations Up 47.1% YoY Yahoo Finance

WuXi AppTec Lists H Shares on the Hong Kong Stock Exchange - WuXi AppTec

WuXi AppTec Lists H Shares on the Hong Kong Stock Exchange WuXi AppTec

WuXi AppTec Testing Facilities Complete Three Regulatory Inspections from US FDA, OECD, and CNAS with Excellent Results - WuXi AppTec

WuXi AppTec Testing Facilities Complete Three Regulatory Inspections from US FDA, OECD, and CNAS with Excellent Results WuXi AppTec

WuXi AppTec's Changzhou and Taixing API Sites Successfully Pass FDA Inspections - PR Newswire

WuXi AppTec's Changzhou and Taixing API Sites Successfully Pass FDA Inspections PR Newswire

WuXi AppTec (603259): Company Profile, Stock Price, News, Rankings - Fortune

WuXi AppTec (603259): Company Profile, Stock Price, News, Rankings Fortune

Highly Selective Novel Heme Oxygenase-1 Hits Found by DNA-Encoded Library Machine Learning beyond the DEL Chemical Space - ACS Publications

Highly Selective Novel Heme Oxygenase-1 Hits Found by DNA-Encoded Library Machine Learning beyond the DEL Chemical Space ACS Publications

WuXi AppTec Announces Record-Breaking 102% Profit Surge: Strong Growth Across All Metrics - Stock Titan

WuXi AppTec Announces Record-Breaking 102% Profit Surge: Strong Growth Across All Metrics Stock Titan

WuXi Advanced Therapies and A*STAR announce partnership to advance cell and gene therapy in the Asia-Pacific region - PR Newswire

WuXi Advanced Therapies and A*STAR announce partnership to advance cell and gene therapy in the Asia-Pacific region PR Newswire

WuXi STA to Purchase Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland - Bristol Myers Squibb

WuXi STA to Purchase Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland Bristol Myers Squibb

WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma - PR Newswire

WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma PR Newswire

DNA-Compatible Cyclization Reaction to Access 1,3,4-Oxadiazoles and 1,2,4-Triazoles - ACS Publications

DNA-Compatible Cyclization Reaction to Access 1,3,4-Oxadiazoles and 1,2,4-Triazoles ACS Publications

WuXi AppTec Receives AA ESG Rating from MSCI - PR Newswire

WuXi AppTec Receives AA ESG Rating from MSCI PR Newswire

Triaging of DNA-Encoded Library Selection Results by High-Throughput Resynthesis of DNA–Conjugate and Affinity Selection Mass Spectrometry - ACS Publications

Triaging of DNA-Encoded Library Selection Results by High-Throughput Resynthesis of DNA–Conjugate and Affinity Selection Mass Spectrometry ACS Publications

NEOM and WuXi AppTec sign strategic MoU to advance Saudi Arabia’s biotech sector - ZAWYA

NEOM and WuXi AppTec sign strategic MoU to advance Saudi Arabia’s biotech sector ZAWYA

WuXi AppTec Expands Site in the U.S. for Drug Development Testing Services - PR Newswire

WuXi AppTec Expands Site in the U.S. for Drug Development Testing Services PR Newswire

1,2,3‐Triazole hybrids with anti‐HIV‐1 activity - Feng - 2021 - Archiv der Pharmazie - Wiley Online Library

1,2,3‐Triazole hybrids with anti‐HIV‐1 activity - Feng - 2021 - Archiv der Pharmazie Wiley Online Library

WuXi AppTec Appoints Edward Hu as Co-CEO - PR Newswire

WuXi AppTec Appoints Edward Hu as Co-CEO PR Newswire

WuXi STA Changzhou Site Passes First U.S. FDA Inspection - 美通社

WuXi STA Changzhou Site Passes First U.S. FDA Inspection 美通社

Wuxi Pharmatech Well Positioned To Continue Growing As Independent Company; Will Receive Breakup Fee Of $30M - Pharmaceutical Online

Wuxi Pharmatech Well Positioned To Continue Growing As Independent Company; Will Receive Breakup Fee Of $30M Pharmaceutical Online

WuXi AppTec’s Global Footprint: Serving Partners Across Asia, Europe, and North America - isStories

WuXi AppTec’s Global Footprint: Serving Partners Across Asia, Europe, and North America isStories

WuXi AppTec: Integrating in Local European Ecosystems for Sustainable Growth - isStories

WuXi AppTec: Integrating in Local European Ecosystems for Sustainable Growth isStories

How WuXi AppTec’s CRDMO Model Drives Business Growth - isStories

How WuXi AppTec’s CRDMO Model Drives Business Growth isStories

Top Wuxi Apptec, Laboratory Testing Division Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant